Bioaffinity Technologies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
bioAffinity Technologies reported a 34% consolidated revenue decrease to $6.2 million in 2025, driven by strategic divestitures, while its CyPath Lung diagnostic revenue surged 87% and the company raised $16.9 million in equity.
NASDAQ
bioAffinity Technologies files an amendment to its annual report on Form 10-K to include information required by Part III regarding directors, executive officers, and corporate governance.
NASDAQ
10-K: bioAffinity Technologies Reports Increased Revenue, Outlines Strategic Actions in Annual 10-K Filing
bioAffinity Technologies' 10-K filing reveals a 270% revenue increase driven by the PPLS acquisition, alongside strategic cost-saving measures and continued focus on CyPath Lung commercial growth.
NASDAQ
10-K: BioAffinity Technologies Details Registered Securities and Corporate Governance in 10-K Filing
BioAffinity Technologies outlines the terms of its common stock and tradeable warrants, along with corporate governance and risk factors, in its annual 10-K filing.